Tamtam Try Tamtam free
Philips logo

Philips account plan

Improving health through innovation

At a glance

Royal Philips is an Amsterdam-based health technology company with EUR 17,834 million of 2025 sales and about 65,000 employees.

Royal Philips (Koninklijke Philips N.V.) is a health technology company that sells imaging, interventional, monitoring and informatics platforms to hospitals and health systems, and grooming, oral care and mother-and-child products to consumers. It is headquartered in Amsterdam, present in 71 countries and employs about 65,000 people, with R&D centred on Eindhoven, Cambridge (US), Bengaluru and Beijing. In FY2025 sales were EUR 17,834 million (-1% nominal, +2% comparable), Adjusted EBITA EUR 2,195 million (12.3% margin) and net income EUR 897 million, after a loss of EUR (698) million in 2024. Health systems revenue mixes product sales, service fees, per-procedure fees, software licences and as-a-service contracts; Personal Health sells through retailers, online platforms and direct-to-consumer.

Business units

Strategic priorities

Profitable growth plan 2026-2028
Mid-single-digit comparable sales CAGR, a mid-teens Adjusted EBITA margin in 2028 and EUR 4.5-5.0 billion of cumulative free cash flow, set at the Capital Markets Day on February 10, 2026.
Disproportionate focus on Monitoring and Interventional
Segment-specific strategies replace the earlier 70-30 split; Image Guided Therapy targets mid-to-high-single-digit growth and an adjusted EBITA above 20% by 2028, and Connected Care a clear path to mid-teens margins.
AI and platform innovation
AI-powered platforms such as Azurion Eye, Verida spectral CT, helium-free 3.0T MRI and the ECG AI Marketplace, built on an installed base of more than 2.5 million systems, with partners AWS, Nvidia and Mayo Clinic.
EUR 1.5 billion productivity programme
Savings over 2026-2028 from cost competitiveness (CT platforms from seven to three), central functions cut 15% to 20% toward first-quartile benchmarks, and AI; EUR 258 million delivered year-to-date by Q2 2026.
Patient safety and quality
Respironics remains under the US consent decree, with no new sleep therapy or respiratory device sales in the US; an FDA warning letter followed inspections in September 2025. US sleep therapy re-entry is not included in the plan.
Regional growth engines
North America is the core growth engine, with large health systems seeking fewer, deeper partnerships; Europe posted double-digit order growth in Q2 2026; India, Indonesia and Saudi Arabia are named growth markets while China is handled selectively.

Latest results

In Q2 2026 Philips posted sales of EUR 4,360 million, +1% nominal and +4% comparable, with growth in all three segments. Adjusted EBITA was EUR 717 million, a 16.4% margin that includes a US tariff refund benefit; the underlying margin was 12.2%. Comparable order intake fell 1% as large North American Monitoring orders moved into Q3, after six consecutive quarters of growth, while the equipment order book stayed at a record level. First-half 2026 sales were EUR 8,265 million (+4% comparable). Philips reiterated 2026 comparable sales growth of 3%-4.5% and raised its Adjusted EBITA margin outlook to 13.5%-14.0% (including about 1% from the refund) and free cash flow to EUR 1.5-1.7 billion.

Investments and deals

SpectraWAVE acquisition
Coronary vascular imaging company acquired January 15, 2026; goodwill of EUR 169 million and contingent consideration of up to EUR 65 million tied to regulatory and revenue milestones.
US manufacturing and R&D
USD 150 million announced to expand US manufacturing and R&D, including ultrasound in Reedsville, Pennsylvania and Image Guided Therapy in Plymouth, Minnesota.
Capital expenditure
Net capital expenditures of EUR 660 million in 2025, in line with 2024; R&D held at around 9% of sales with fewer, bigger programmes.
Divestments
Emergency Care sold in 2025 (now Heartstream) among two divestments for EUR 77 million; the electronic medical records business was divested in Q2 2026, with a EUR 99 million gain.

Challenges and risks

Tariffs and cost inflation
Tariffs rose from about 1% to about 3% of cost of sales in 2025; e-components, freight and energy inflation cut the underlying Diagnosis & Treatment margin to 9.3% in Q2 2026.
China
Health systems sales in China are weak as centralised procurement expands; Precision Diagnosis declined low-single-digit partly because of China.
Respironics legal and regulatory exposure
Investigations by the SEC, DoJ, State Attorneys General and Australia's TGA continue, alongside securities claims and an Amsterdam Enterprise Chamber inquiry request.
Slow informatics transition
Enterprise Informatics sales declined mid-single-digit in Q2 2026 as customers move to cloud; orders take 12 to 18 months to turn into revenue.
Order-to-sales conversion
Larger deals and constrained installation capacity slow the conversion of orders into sales.

What leadership says

“Today marks the beginning of a next phase for Philips. We have stabilised the company, significantly improved our culture, our team and the fundamentals of our business.”

Roy Jakobs, CEO · Philips Capital Markets Day 2026, February 10, 2026

“In healthcare, AI is augmenting instead of replacing people”

Roy Jakobs, CEO · Philips Capital Markets Day 2026, February 10, 2026

“We delivered another solid quarter with comparable sales growth of 4%, driven by all business segments”

Roy Jakobs, CEO · Philips Quarterly Report Q2 2026, July 27, 2026

“In 2025, we delivered on our commitments and drove performance every quarter”

Charlotte Hanneman, CFO · Philips Annual Report 2025

Where a supplier can help

Productivity and central-function savings
The EUR 1.5 billion productivity programme and the 15% to 20% central-functions reduction open room for suppliers of automation, AI agents and process tooling that cut cost per transaction.
Supply chain and tariff mitigation
Tariff and e-component inflation, plus the regionalisation and dual-sourcing push, favour suppliers of components, logistics and sourcing analytics that help localise production.
Cloud and AI informatics
The move of Enterprise Informatics to cloud and SaaS and the AI platform agenda create demand for cloud, data, cybersecurity and AI regulatory-compliance partners.
Installation and service capacity
Constrained installation capacity slows order-to-sales conversion; field service, installation and project-management partners could help turn the record order book into revenue.
Quality and regulatory compliance
The Respironics consent decree and the FDA warning letter make quality management, regulatory documentation and audit tooling a standing need.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Philips?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Philips

What does Philips do?

Philips is a health technology company selling imaging, image-guided therapy, patient monitoring and informatics to hospitals, and personal health products such as Sonicare toothbrushes and shavers to consumers.

What is Philips' revenue?

FY2025 sales were EUR 17,834 million, up 2% comparable, with Adjusted EBITA of EUR 2,195 million. First-half 2026 sales were EUR 8,265 million.

How many people work at Philips?

About 65,000 employees, in 71 countries, according to the 2025 annual report.

What is Philips' strategy to 2028?

Mid-single-digit comparable sales growth, a mid-teens Adjusted EBITA margin in 2028, EUR 4.5-5.0 billion cumulative free cash flow and EUR 1.5 billion of productivity savings, with extra focus on Monitoring and Interventional and on AI-powered platforms.

Who leads Philips?

Roy Jakobs has been CEO since October 2022, with Charlotte Hanneman as CFO; the Supervisory Board is chaired by Feike Sijbesma.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)